Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma

Detalles Bibliográficos
Autores principales: Kagdi, Huseini, Fields, Paul, Hodson, Andrew, Taylor, Graham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044561/
http://dx.doi.org/10.1186/1742-4690-11-S1-P8
_version_ 1782319166640881664
author Kagdi, Huseini
Fields, Paul
Hodson, Andrew
Taylor, Graham
author_facet Kagdi, Huseini
Fields, Paul
Hodson, Andrew
Taylor, Graham
author_sort Kagdi, Huseini
collection PubMed
description
format Online
Article
Text
id pubmed-4044561
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40445612014-06-19 Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma Kagdi, Huseini Fields, Paul Hodson, Andrew Taylor, Graham Retrovirology Poster Presentation BioMed Central 2014-01-07 /pmc/articles/PMC4044561/ http://dx.doi.org/10.1186/1742-4690-11-S1-P8 Text en Copyright © 2014 Kagdi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Kagdi, Huseini
Fields, Paul
Hodson, Andrew
Taylor, Graham
Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
title Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
title_full Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
title_fullStr Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
title_full_unstemmed Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
title_short Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
title_sort case reports: combination therapy with proteasome inhibitor bortezomib and humanized anti-cd25 basiliximab for treatment of adult t cell leukaemia lymphoma
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044561/
http://dx.doi.org/10.1186/1742-4690-11-S1-P8
work_keys_str_mv AT kagdihuseini casereportscombinationtherapywithproteasomeinhibitorbortezomibandhumanizedanticd25basiliximabfortreatmentofadulttcellleukaemialymphoma
AT fieldspaul casereportscombinationtherapywithproteasomeinhibitorbortezomibandhumanizedanticd25basiliximabfortreatmentofadulttcellleukaemialymphoma
AT hodsonandrew casereportscombinationtherapywithproteasomeinhibitorbortezomibandhumanizedanticd25basiliximabfortreatmentofadulttcellleukaemialymphoma
AT taylorgraham casereportscombinationtherapywithproteasomeinhibitorbortezomibandhumanizedanticd25basiliximabfortreatmentofadulttcellleukaemialymphoma

Ejemplares similares